Genetic code expansion (GCE) technology, by enabling the ribosomal, site-specific incorporation of non-canonical amino acids (ncAAs), provides a surgical method to install novel chemical functionalities, enhanced stability, or bioorthogonal handles directly into peptides and proteins. This foundational capability addresses core challenges in therapeutic peptide development, such as poor metabolic stability and limited structural diversity. Specializing in the development of high-throughput orthogonal aaRS/tRNA pairs, we integrate our proprietary GCEngine platform with advanced peptide engineering to bridge the gap between innovative chemistry and viable drug candidates.
Non-canonical amino acid incorporated peptide therapy moves beyond the constraints of the 20 natural amino acids, offering a method to rationally design peptide drugs with augmented properties. Traditional therapeutic peptides, while offering high specificity and potency, often face challenges related to rapid in vivo clearance, enzymatic degradation, and limited membrane permeability.
Fig.1 The development of MK-0616 involved hit-to-lead optimization from mRNA display compound 1 to lead 2, with key chemical modifications highlighted. (Gare, C. L., et al., 2025)
The strategic introduction of ncAAs can address these hurdles. For instance, incorporating D-amino acids or N-methylated residues can confer protease resistance, while side chains bearing azide or alkyne groups enable site-specific conjugation (e.g., for PEGylation or payload attachment). This approach transcends simple mimicry of natural hormones, allowing for the creation of optimized and novel peptide entities with tailor-made functionalities for complex therapeutic indications.
Applications
The strategic incorporation of ncAAs into therapeutic peptides enables novel functionalities that are unattainable with natural amino acids alone, opening distinct applications across modern biopharmaceutical development.
Advantages
Integrating ncAAs into a peptide framework provides a decisive edge over traditional synthetic or recombinant methods by combining the precision of genetic encoding with the versatility of synthetic chemistry.
The GCEngine platform at our company is dedicated to the high-throughput discovery and optimization of orthogonal aaRS/tRNA pairs, capable of efficiently incorporating a diverse array of ncAAs into target peptides. We couple this with deep expertise in peptide chemistry, in vitro validation, and in vivo application. Our integrated service for ncAA-incorporated peptide therapy development is designed to guide clients from concept and molecular design through to the delivery of characterized, functional candidate molecules, ready for preclinical assessment.
Our versatile GCEngine platform is engineered to support a broad spectrum of development objectives, from straightforward site-specific modifications to the design of sophisticated, multifunctional peptide therapeutics.
Site-Specific Conjugation Handles
Incorporating a single bioorthogonal ncAA (e.g., p-azido-L-phenylalanine, homopropargylglycine) to enable precise, site-specific conjugation for applications such as PEGylation, fluorophore labeling, or attachment of cytotoxic payloads.
Probes & Diagnostic Tools
Development of high-precision research tools containing photo-crosslinkers, environmentally sensitive fluorophores, or isotopic labels for mechanistic studies, target engagement assays, or diagnostic applications, and accelerating early-stage therapeutic discovery.
Peptide Stabilization and Optimization
Addressing challenges of peptide stability and bioavailability through ncAA incorporation that introduces steric hindrance or backbone modifications. This includes the use of ncAA-mediated peptide stapling/cyclization to enhance metabolic stability and lock bioactive conformations for improved potency.
Multi-Site Incorporation
Through advanced GCE strategies, including mutually orthogonal aaRS/tRNA pairs or expanded genetic code systems, we enable the incorporation of multiple ncAAs within a single peptide sequence. This supports the development of multifunctional therapeutics with precise chemical control.
Our platform provides tailored therapeutic peptide development services across key disease areas. By leveraging site-specific ncAA incorporation, we engineer peptides to overcome indication-specific biological challenges, from target engagement to in vivo delivery.
Focused on the creation of high-potency PDCs and immune-modulators, this service utilizes site-specific ncAA incorporation to enhance tumor penetration and minimize off-target toxicity.
Inflammatory & Autoimmune Diseases
Engineering of immunomodulatory peptides. ncAAs help stabilize inhibitory structures and enable covalent binding for sustained, specific inhibition of inflammatory pathways.
Design of antimicrobial and antiviral peptides. ncAA incorporation aims to enhance protease resistance and improve selectivity against pathogens while minimizing host toxicity.
Other Key Areas
Centered on the optimization of hormone analogs and enzyme replacement therapies, this category focuses on achieving prolonged systemic circulation and improved receptor selectivity.
By integrating cutting-edge GCE science with robust peptide development expertise, we provide a unique and reliable partnership for innovating at the frontier of biologic therapeutics. Our platform is designed to de-risk and accelerate the journey from a novel concept to a therapeutic candidate with a compelling preclinical profile. To explore how our GCEngine platform can elevate your ncAA-incorporated peptide therapy development program, please contact our technical team.
All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.
A specialized platform advancing genetic code expansion through orthogonal tRNA/aaRS technologies, enabling precise ncAA incorporation for biotherapeutic development, synthetic biology, and diagnostics.